



Overcoming chemotherapy resistance

Q3 Webcast – November 20, 2020 at 10:00 CET





**90% of cancer deaths are related to
cancer drug resistance**

Company Highlights from 3Q - now

First Data - cohort I

On **July 31st**, Scandion Oncology reported on data from the first patient from cohort I of the first part of the clinical phase II study enrolling chemotherapy resistant colorectal cancer patients treated with SCO-101 and chemotherapy (FOLFIRI).

New CEO and CSO

On **September 16th**, Scandion Oncology appointed Bo Rode Hansen as new President & CEO and co-founder Nils Brünner as new CSO in order to strengthen executive leadership, and secure corporate- and pipeline development towards upcoming value inflection points for Scandion Oncology

Second trial approval

On **September 28th**, Scandion Oncology announced that the Company had received final approval from the Danish Medicines Agency and Ethical Committee to initiate a clinical trial with the drug candidate SCO-101 in combination with first line chemotherapy in patients with metastatic pancreatic cancer. Results from this trial are expected in Q2-Q3, 2021.

Second trial initiated

On **October 28th**, Scandion Oncology announced that its second clinical study with SCO-101 has been initiated. This Phase Ib study enrolls metastatic pancreatic cancer patients who will receive SCO-101 together with 1st line standard chemotherapy (Nab-paclitaxel plus gemcitabine) in cohorts of three. The endpoints of this study are safety and efficacy, and the results are expected to be released Q2-Q3, 2021.

236 M SEK Rights issue secured

On **November 16th**, Scandion Oncology announced that the Board of Directors had, pursuant to the authorization granted by the extraordinary general meeting on 13 November 2020, resolved on a fully guaranteed new share issue of 10,711,848 shares with preferential rights for the Company's existing shareholders (the "Rights Issue"). The subscription price in the Rights Issue is SEK 22 per share. The Company will receive SEK 235,660,656 prior to deduction of transaction costs.

Overview of the rights issue of SEK 236 million




A rights issue is an invitation to existing shareholders to purchase new shares in the company. In a rights issue, each shareholder receives the right (subscription right) to retain an equal percentage ownership (pro-rata) by subscribing for additional shares at a specific price, within a specific time period.

Information regarding the rights issue

16 November 2020 Scandion Oncology announced a fully guaranteed rights issue of approximately SEK 236 million. The net proceeds of approximately SEK 200 million from the rights issue are intended to finance the following activities,

- Approximately 60% will be used for continued development of SCO-101, including drug production and clinical trials
- Approximately 10% will fund pre-clinical development of SCO-201 and explorations and additional indications of SCO-01
- Approximately 30% will support general company activities

Pipeline



Colorectal Cancer

First Data -
cohort I

Pancreatic Cancer

Second trial
approval

Second trial
initiated

Key figures and selected financial posts

Loss before tax
Q3 2020

5.0 MDKK
(7.3 MDKK)

Loss before tax
Q1 – Q3 2020

14.1 MDKK
(14.7 MDKK)

Earnings per share
Q1 – Q3 2020

-0.58 DKK/share
(-0.63 DKK/share)

Number of shares
30 September 2020

19.1 million
(19.1 million)

Danish Company listed on Spotlight Stock Market

- Currency DKK (SCOL share traded in SEK)
- Danish Financial Statements Act
- Quarterly report NOT audited

Results

- Pre-tax loss YTD Q3 is 14.1 MDKK
- Costs and losses are in line with plans and expectations
- Going concern statement is issued in annual report NOT quarterly report
- No commitments beyond what can be fulfilled

Shares

- Number of shares 19.1 million
- Exercise of warrants of series TO 1 has increased number of shares to 21.4 million
- Rights issue Nov/Dec might increase number of shares to 32.1 million

Cash flow statement




Cash burn

0.8 MDKK
(1.1 MDKK)

Cash position
30 September 2020

7.5 MDKK



Cash

- Cash burn 0.8 MDKK (1.1 MDKK)
- Cash burn low due to tax credit scheme on R&D costs and postponement of tax payments due to COVID-19
- Cash position 30 September 2020 7.5 MDKK

Capital increases

- Warrants of series TO1 provided 12.3 MSEK before issue costs – net proceeds app. 8.0 MDKK
- Rights issue Nov/Dec might provide app. 235 MSEK – net proceeds app. 140 MDKK

Overview of the rights issue of SEK 236 million



1 existing share → 1 subscription right

2 subscription rights → 1 new share

Subscription price: SEK 22 per share

SEK 236 million

Important dates

**24
November**

Record date and
publication of
prospectus

**26
November**

Start of
subscription
period

8 December

Last day of
trading in
subscription
rights

**10
December**

End of
subscription
period

**Around 15
December**

Announcement
of outcome

Summary of the rights issue



Summary of rights issue of new shares

For shareholders who on the record date, 24 November 2020, was registered as a shareholder in the shareholder register held by Euroclear Sweden on behalf of Scandion Oncology, receive subscription rights in proportion to their existing shareholdings. Those who on the record date were registered as shareholders of Scandion Oncology have preferential rights to subscribe for new shares in the rights issue. For one (1) existing share held on the record date the holder receives one (1) subscription right. Two (2) subscription rights entitles to subscription for one (1) new share.

Subscription price

The subscription price is SEK 22.00 SEK per share.

Preliminary timetable for the rights issue

Subscription period:	26 November 2020 – 10 December 2020
Trading in subscription rights:	26 November 2020 – 8 December 2020
Trading in BTA:	26 November 2020 until the Danish Business Authority has registered the rights issue and BTAs are converted to shares
Size of transaction:	Approximately SEK 236 million
Guarantees:	The rights issue is fully guaranteed through subscription undertakings and guarantee undertakings
Settlement:	Payment shall be made not later than three (3) banking days after the issuance of the settlement notes

Full terms

The full terms and conditions of the rights issue and information about the Company will be included in a prospectus expected to be published on the Company's website around 24 November 2020.

Issuing Agent

Hagberg & Aneborn Fondkommission AB
114 41 Stockholm, Sweden
info@hagberganeborn.se



Disclaimer

*This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "**Presentation**"), has been prepared by Scandion Oncology A/S ("**Scandion Oncology**" or the "**Company**"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.*

*This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and the Presentation does not constitute, and should not be considered as, a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 and do not constitute an offer to acquire securities in the Company. The Presentation is intended to present background information on the Company, its business and the industry in which it shares inoperates and is not intended to provide complete disclosure. The Company has prepared a prospectus which is expected to be approved by and registered with the Swedish Financial Supervisory Authority (the "**SFSA**") around 24 November 2020 (the "**Prospectus**") relating to a preferential rights issue of approximately SEK 236 million resolved upon by the Company's board of directors on 16 November (the "**rights issue**"). The Prospectus presents risks connected to an investment in the Company, and prospective investors in the rights issue are advised to read the Prospectus in its entirety before making a decision whether to invest in the Company. The expected approval from SFSA of the Prospectus should not be understood as an endorsement of the securities offered. The the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.*

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors in the rights issue should not place undue reliance on forward-looking statements. They speak only as at the date of this Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company does not undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Swedish law. The courts of Sweden, with the District Court of Stockholm as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.



Q&A

A horizontal band across the middle of the slide featuring a blurred image of laboratory glassware, including beakers and test tubes, with a light blue overlay.

End